Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo.

Jin HJ, Zhang H, Sun ML, Zhang BG, Zhang JW.

J Thromb Thrombolysis. 2013 Nov;36(4):458-68. doi: 10.1007/s11239-013-0951-7.

PMID:
23728739
2.

Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.

Bagre AP, Jain K, Jain NK.

Int J Pharm. 2013 Nov 1;456(1):31-40. doi: 10.1016/j.ijpharm.2013.08.037.

PMID:
23994363
3.
4.
5.

Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.

Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.

Circulation. 1991 Sep;84(3):1216-34.

PMID:
1909220
7.

Thrombolysis based on magnetically-controlled surface-functionalized Fe3O4 nanoparticle.

Chang M, Lin YH, Gabayno JL, Li Q, Liu X.

Bioengineered. 2017 Jan 2;8(1):29-35.

PMID:
27689864
10.

Catheter-directed thrombolysis with percutaneous rheolytic thrombectomy versus thrombolysis alone in upper and lower extremity deep vein thrombosis.

Kim HS, Patra A, Paxton BE, Khan J, Streiff MB.

Cardiovasc Intervent Radiol. 2006 Nov-Dec;29(6):1003-7.

PMID:
16967220
11.

Ultrasound-triggered thrombolysis using urokinase-loaded nanogels.

Jin H, Tan H, Zhao L, Sun W, Zhu L, Sun Y, Hao H, Xing H, Liu L, Qu X, Huang Y, Yang Z.

Int J Pharm. 2012 Sep 15;434(1-2):384-90. doi: 10.1016/j.ijpharm.2012.06.001.

PMID:
22683455
12.

Targeted thrombolysis by using of magnetic mesoporous silica nanoparticles.

Wang M, Zhang J, Yuan Z, Yang W, Wu Q, Gu H.

J Biomed Nanotechnol. 2012 Aug;8(4):624-32.

PMID:
22852472
13.

Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.

Marsh JN, Senpan A, Hu G, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM.

Nanomedicine (Lond). 2007 Aug;2(4):533-43.

PMID:
17716136
16.

Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons.

Mitchel JF, Azrin MA, Fram DB, Hong MK, Wong SC, Barry JJ, Bow LM, Curley TM, Kiernan FJ, Waters DD, et al.

Circulation. 1994 Oct;90(4):1979-88.

PMID:
7923688
17.

Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis.

Bi F, Zhang J, Su Y, Tang YC, Liu JN.

Biomaterials. 2009 Oct;30(28):5125-30. doi: 10.1016/j.biomaterials.2009.06.006.

PMID:
19560812
18.

Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life.

Comerota AJ, Throm RC, Mathias SD, Haughton S, Mewissen M.

J Vasc Surg. 2000 Jul;32(1):130-7.

19.

[Study on chitosan-modified tripterygium glycoside nanoparticles and its renal targeting property].

Chen XK, Wei YH, Yao JN, Zhao YM, Shang XG, Li FZ.

Zhongguo Zhong Yao Za Zhi. 2013 Feb;38(4):548-52. Chinese.

PMID:
23713281
20.

Adjunctive percutaneous mechanical thrombectomy for lower-extremity deep vein thrombosis: clinical and economic outcomes.

Kim HS, Patra A, Paxton BE, Khan J, Streiff MB.

J Vasc Interv Radiol. 2006 Jul;17(7):1099-104.

PMID:
16868161

Supplemental Content

Support Center